Campos-Parra, Alma D <br/><br/>
KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.  [electronic resource] 

 -  American journal of clinical oncology  Feb 2015 
 - 33-40 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1537-453X 
<br/><br/><label>Standard No.: </label>10.1097/COC.0b013e318287bb23  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carboplatin--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cisplatin--administration & dosage<br/>Disease-Free Survival<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Genetic Markers<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Paclitaxel--administration & dosage<br/>Prognosis<br/>Protein Kinase Inhibitors--therapeutic use<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins p21(ras)<br/>Treatment Outcome<br/>Vinblastine--administration & dosage<br/>Vinorelbine<br/>ras Proteins--genetics